Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Amgen
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)
To assess the effect of anemia therapy with darbepoetin alfa on the composite event comprising all-cause mortality and cardiovascular (CV) events (including myocardial ischemia, congestive heart failu...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral Density
The primary objective is to evaluate the effect of denosumab 60 mg q 6 months on total hip bone mineral density (BMD) at 12 months in postmenopausal women with low BMD previously treated with alendron...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
Study to access whether AMG 145, in people with dyslipidemia, who cannot tolerate an effective dose of a statin, causes any side effects and to confirm that treatment with AMG 145 will lower LDL-cholesterol and increase HDL-cholesterol. To do this, AMG 145 will be compared with ezetimibe which is a cholesterol-lowering medication used to help patients manage cholesterol levels
To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145 every 2 weeks (Q2W) and monthly (QM), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (L...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Amgen (Germany)
MAJ Il y a 4 ans
Capecitabine with/without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
Efficacy and Safety Study of Romiplostim in Paediatrics with Immune Thrombocytopenia
The primary objective is to describe the percentage of time that pediatric subjects with immune thrombocytopenia (ITP) have a platelet response in the first 6 months from the start of treatment with r...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
To determine the treatment effect of AMG 162 compared with placebo on lumbar spine bone mineral density (BMD) in men with nonmetastatic prostate cancer undergoing ADT.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
A Study to Test the Effect and Safety of Brodalumab Compared With Placebo and Ustekinumab and the Results of Changing Strength or Frequency of Brodalumab in People with Moderate to Severe Plaque Psoriasis: AMAGINE-2
Primary Placebo-family Objectives Compared with placebo: • To evaluate the efficacy of brodalumab (210 mg every 2 weeks [Q2W]; and 140 mg Q2W) in subjects with moderate to severe plaque psoriasis, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Amgen
MAJ Il y a 4 ans
Amgen PRIME : Essai de phase 3 randomisé comparant l’efficacité de la combinaison de l’oxaliplatine, du 5-FU et de l’acide folinique, associé ou non au panitumumab, chez des patients ayant un cancer colorectal métastatique non prétraité. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité du panitumumab associé à une chimiothérapie comprenant de l’oxaliplatine, du 5-fluorouracile et de l’acide folinique dans le traitement de patients a...
Pays
France
Organes
Côlon ou Rectum (colorectal)
Spécialités
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Part 1 (Phase 1b): To determine the maximum tolerated dose up to a target dose of 15 mg/kg of AMG 655 that can be administered in combination with paclitaxel/carboplatin Part 2 (Phase 2): To estimat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer
To describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received denosumab
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
10
11
12
13
14
15
16
17
18
19
Suivant